Clinical Applications of Photobiomodulation Therapy in the Management of Breast Cancer-related Lymphedema

Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Unfortunately, treatments often fail because of the development of drug resistance, the underlying mechanisms of which remain unclear. Circulating tumor DNA (ctDNA) is free DNA released into the blood by necrosis, apoptosis or direct secretion by tumor cells. In contrast to repeated, highly invasive tumor biopsies, ctDNA reflects all molecular alterations of tumors dynamically and captures both spatial and temporal tumor heterogeneity. Highly sensitive technologies, including personalized digital PCR and deep sequencing, make it possible to monitor response to therapies, predict drug resistance and tailor treatment regimens by identifying the genomic alteration profile of ctDNA, thereby achieving precision medicine. This review focuses on the current status of ctDNA biology, the technologies used to detect ctDNA and the potential clinical applications of identifying drug resistance mechanisms by detecting tumor-specific genomic alterations in breast cancer.

Download Full-text

Electronic Moxibustion for Breast Cancer-Related Lymphedema: A Pilot Clinical Trial

Integrative Cancer Therapies ◽

10.1177/1534735420962854 ◽

2020 ◽

Vol 19 ◽

pp. 153473542096285

Author(s):

Kyungsun Han ◽

Ojin Kwon ◽

Hyo-Ju Park ◽

Ae-Ran Kim ◽

Boram Lee ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Range Of Motion ◽

Upper Limb ◽

Life Questionnaire ◽

Breast Cancer Patients ◽

Shoulder Range Of Motion ◽

Breast Cancer Related Lymphedema ◽

Shoulder Range

This is a preliminary study to investigate the feasibility of electronic moxibustion in breast cancer patients with upper limb lymphedema. As current treatment options for lymphedema are unsatisfactory and time consuming, there have been attempts to manage symptoms using integrative treatments. Electronic moxibustion was developed to compensate for the shortcomings of conventional moxibustion and is widely used in clinical practice. However, there have been no studies on using electronic moxibustion in breast cancer-related lymphedema. To investigate the feasibility of electronic moxibustion in treating breast cancer-related lymphedema, this study included subjects who completed primary cancer treatment at least 6 months ago and had more than 10 mm difference in arm circumference of upper limbs. All subjects were assigned to the treatment group. Subjects were treated with 16 sessions (30 minutes/session) of electronic moxibustion for 8 weeks followed by 4 weeks of follow-up. For outcome measures, upper limb circumferences, shoulder range of motion, bioimpedance analysis, and quality of life questionnaire were assessed. All 10 subjects completed the study. The effective index showed 38.21% reduction after treatment ( P = .0098) and 29.35% ( P = .0039) after 4 weeks of follow-up compared to the baseline. The reduction of lymphedema was most prominent at 10 cm above the elbow crease, where the mean reduction of circumference difference was 7.5 mm ( P = .0430) and continued to improve after treatment (mean reduction of 8.3 mm, P = .0156). There was significant improvement in shoulder range of motion only in flexion and internal rotation at week 9. There were 7 adverse events, and most were irrelevant to the treatment. Only 1 participant had a mild burn on the acupuncture point. Here, we demonstrate for the first time that electronic moxibustion treatment is a feasible treatment for breast cancer-related lymphedema. Electronic moxibustion may reduce differences in upper limb circumference and improve shoulder range of motion. A future comparative clinical trial is needed to confirm the clinical efficacy of this treatment.

Download Full-text

The association of breast cancer related lymphedema after unilateral mastectomy with shoulder girdle kinematics and upper extremity function

Journal of Biomechanics ◽

10.1016/j.jbiomech.2021.110432 ◽

2021 ◽

pp. 110432

Author(s):

Emine Baran ◽

Taha İbrahim Yildiz ◽

Ceren Gursen ◽

Esra Üzelpasaci ◽

Serap Özgül ◽

...

Keyword(s):

Breast Cancer ◽

Upper Extremity ◽

Shoulder Girdle ◽

Extremity Function ◽

Upper Extremity Function ◽

Breast Cancer Related Lymphedema ◽

Unilateral Mastectomy

Download Full-text

Prospective Validation of Indocyanine Green Lymphangiography Staging of Breast Cancer-Related Lymphedema

Cancers ◽

10.3390/cancers13071540 ◽

2021 ◽

Vol 13 (7) ◽

pp. 1540

Author(s):

Mads Gustaf Jørgensen ◽

Navid Mohamadpour Toyserkani ◽

Frederik Christopher Gulmark Hansen ◽

Jørn Bo Thomsen ◽

Jens Ahm Sørensen

Keyword(s):

Breast Cancer ◽

Indocyanine Green ◽

Clinical Severity ◽

Serious Adverse Events ◽

Disease Information ◽

Grading Systems ◽

Breast Cancer Related Lymphedema ◽

Disease Stratification ◽

Md Anderson ◽

Clinical Measurements

Indocyanine green lymphangiography (ICG-L) allows real-time investigation of lymphatics. Plastic surgeons performing lymphatic reconstruction use the ICG-L for patient selection and stratification using the MD Anderson (MDA) and the Arm Dermal Backflow (ADB) grading systems. However, the applicability of ICG-L in evaluating breast cancer-related lymphedema (BCRL) is sparse and not well established. This study comprehensively examines the usability of ICG-L in the assessment of BCRL. We prospectively performed ICG-L in 237 BCRL patients between January 2019 and February 2020. The aim of this study was to assess the interrater and intrarater agreement and interscale consensus of ratings made using the MDA and ADB scales. Three independent raters performed a total of 2607 ICG-L assessments. The ICG-L stage for each grading system was correlated to the lymphedema volume to assess the agreement between the ICG-L stage and clinical severity. The interrater agreement was near perfect for the MDA scale (kappa 0.82–0.90) and the ADB scale (kappa 0.80–0.91). Similarly, we found a near-perfect intrarater agreement for the MDA scale (kappa 0.84–0.94) and the ADB scale (kappa 0.88–0.89). The agreement between the MDA and the ADB scales was substantial (kappa 0.65–0.68); however, the ADB scale systematically overestimated lower ICG-L stages compared to the MDA scale. The volume of lymphedema correlated slightly with MDA stage (Spearmans rho = 0.44, p < 0.001) and ADB stage (rs = 0.35, p < 0.001). No serious adverse events occurred. The staging of BCRL with ICG-L is reliable, safe, and provides unique disease information unobtainable with clinical measurements alone. The MDA scale seems to provide better disease stratification compared to the ADB scale.

Download Full-text